SciNeuro is at the forefront of neuroscience, leveraging significant advancements in understanding the pathophysiology and genetics of brain diseases to develop innovative therapies. The company focuses on translating scientific insights into transformative medicines, particularly for neurodegenerative diseases such as Alzheimer's and Parkinson's. By assembling a team of expert scientists and industry leaders, SciNeuro aims to accelerate therapeutic innovation and address the pressing challenges in central nervous system (CNS) treatment. Their strategic approach is underpinned by a commitment to collaboration with global scientific communities, ensuring that their research is informed by the latest discoveries in the field.

The company’s pipeline is characterized by a growing portfolio of novel medicines targeting critical pathways involved in neurodegeneration. SciNeuro's research emphasizes three main mechanisms: proteinopathy, neurovascular inflammation, and immune response. By developing therapies that clear misfolded proteins, protect and repair vascular structures, and restore immune homeostasis, SciNeuro aims to mitigate the effects of diseases that progressively damage neuronal function. Their investigational therapies are designed to explore the therapeutic potential of drug candidates across a wide range of serious CNS conditions, supported by a robust understanding of disease biology and innovative technology platforms.

China

SciNeuro Pharmaceuticals is an innovation-driven, neuroscience-focused biopharmaceutical company with an established pipeline of novel therapeutic candidates to address neurodegenerative and other CNS diseases. The company focuses on targets that are supported by human biology and which play a critical role in regulating foundation biology, to achieve better probability of success in clinical development. SciNeuro is committed to delivering medicines that can make a difference to improve the lives of patients around the world, transforming scientific discoveries into groundbreaking therapies.

SciNeuro

Company Details